201 related articles for article (PubMed ID: 38236364)
21. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
Wong KM; King GG; Harris WP
Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
[TBL] [Abstract][Full Text] [Related]
22. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
[TBL] [Abstract][Full Text] [Related]
23. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Ferris RL; Haddad R; Even C; Tahara M; Dvorkin M; Ciuleanu TE; Clement PM; Mesia R; Kutukova S; Zholudeva L; Daste A; Caballero-Daroqui J; Keam B; Vynnychenko I; Lafond C; Shetty J; Mann H; Fan J; Wildsmith S; Morsli N; Fayette J; Licitra L
Ann Oncol; 2020 Jul; 31(7):942-950. PubMed ID: 32294530
[TBL] [Abstract][Full Text] [Related]
24. Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations.
Storandt MH; Mahipal A; Tella SH; Kommalapati A; Jin Z
J Hepatocell Carcinoma; 2022; 9():1187-1200. PubMed ID: 36471742
[TBL] [Abstract][Full Text] [Related]
25. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
[TBL] [Abstract][Full Text] [Related]
26. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
27. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.
Kudo M
Int J Clin Oncol; 2022 Jul; 27(7):1110-1119. PubMed ID: 35527313
[TBL] [Abstract][Full Text] [Related]
28. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
[TBL] [Abstract][Full Text] [Related]
30. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
Feng MY; Chan LL; Chan SL
Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
[TBL] [Abstract][Full Text] [Related]
31. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
32. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
33. Dual Immunotherapy Makes Strides against HCC.
Cancer Discov; 2022 Apr; 12(4):OF1. PubMed ID: 35105553
[TBL] [Abstract][Full Text] [Related]
34. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Qin S; Bi F; Gu S; Bai Y; Chen Z; Wang Z; Ying J; Lu Y; Meng Z; Pan H; Yang P; Zhang H; Chen X; Xu A; Cui C; Zhu B; Wu J; Xin X; Wang J; Shan J; Chen J; Zheng Z; Xu L; Wen X; You Z; Ren Z; Liu X; Qiu M; Wu L; Chen F
J Clin Oncol; 2021 Sep; 39(27):3002-3011. PubMed ID: 34185551
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations.
Bejjani AC; Finn RS
J Clin Oncol; 2022 Aug; 40(24):2763-2773. PubMed ID: 35649192
[TBL] [Abstract][Full Text] [Related]
36. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
[TBL] [Abstract][Full Text] [Related]
37. Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations.
Albarrak J; Al-Shamsi H
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046662
[TBL] [Abstract][Full Text] [Related]
38. Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis.
Rizzo A; Carloni R; Ricci AD; Cusmai A; Laforgia M; Calabrò C; Ungaro V; Oreste D; Sollitto M; Palmiotti G; Brandi G
Expert Opin Drug Saf; 2023 Apr; 22(4):323-329. PubMed ID: 36426773
[TBL] [Abstract][Full Text] [Related]
39. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Shimose S; Hiraoka A; Nakano M; Iwamoto H; Tanaka M; Tanaka T; Noguchi K; Aino H; Ogata K; Kajiwara M; Itano S; Yokokura Y; Yamaguchi T; Kawano H; Matsukuma N; Suga H; Niizeki T; Shirono T; Noda Y; Kamachi N; Okamura S; Kawaguchi T; Koga H; Torimura T
Cancer Med; 2021 Dec; 10(23):8530-8541. PubMed ID: 34693661
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
